Jiangsu Aosaikang Pharmaceutical Co., Ltd.

2 in Phase 3

Quick facts

Phase 3 pipeline

ASK120067
ASK120067 is an investigational therapeutic agent in phase 3 development by Jiangsu Aosaikang Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.
ASKC202+ Limertinib · Oncology
ASKC202 is a bispecific antibody targeting EGFR and c-MET, combined with limertinib, a third-generation EGFR tyrosine kinase inhibitor, to overcome resistance in EGFR-mutant lung cancer.

Phase 1 pipeline

ASK120067;itraconazole · Infectious Disease
Azole antifungal agent
ASKB1202
ASKC202
Rifampicin; ASK120067

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Jiangsu Aosaikang Pharmaceutical Co., Ltd.

What is Jiangsu Aosaikang Pharmaceutical Co., Ltd.'s pipeline?

Jiangsu Aosaikang Pharmaceutical Co., Ltd. has 2 drugs in Phase 3, 0 in Phase 2, 4 in Phase 1. Late-stage candidates include ASK120067, ASKC202+ Limertinib.

Sector hub: All tracked pharma companies